Respiratory Control for Speech and Swallowing in Ataxia
The goal of this study is to learn how breath control for speaking and swallowing is impacted in ataxia. The results of this study will set the foundation to see if a treatment focusing on breath control could be beneficial.
Link to Enroll: Click here.
About the Study
Eligible Ataxia Types
SCA (all subtypes) and Friedreich’s Ataxia
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
06/01/2023
Estimated Completion Date
08/01/2024
IRB Approval #
23-0022
Location(s)
CO Motor Speech Lab
2501 Kittredge Loop Drive
Boulder, CO
Contact Information
Allison Hilger
allison.hilger@colorado.edu
630-479-3602
What does participation in the study entail?
Participating in one 2-3 hour testing session in which your speech will be audio and video recorded while we also measure your respiratory patterns using bands around your abdomen and rib cage. Additionally, we will be conducting speech evaluation, cognitive and language screeners, and quality of life questionnaires.
What are the potential benefits for participants?
Participants will receive a free speech evaluation for their records.
What are the potential risks for participants?
The risks are boredom and vocal fatigue.
Is there financial compensation?
Yes. $20/hour.
Is there travel reimbursement?
Yes. For parking.
Who is eligible?
Adults with spinocerebellar ataxia (all subtypes) or Friedreich’s Ataxia.
Link to Enroll
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
